The Maurice Wohl Clinical Neuroscience Institute
The Maurice Wohl Clinical Neuroscience Institute is one of Europe’s largest centres for interdisciplinary neuroscience excellence. Located at the heart of King’s College London’s Denmark Hill Campus, it's home to a unique core of neuroscience research.
The Institute is a key research facility in our efforts to fast-track new treatments to patients affected by disorders such as Alzheimer’s disease, Parkinson’s disease, motor neurone disease, depression, schizophrenia, epilepsy and stroke, while strengthening King’s’ portfolio of internationally recognised brain research.
The 6,500-square-metre Institute brings together 250 clinicians and scientists from many disciplines including: neuroimaging, neurology, psychiatry, genetics, molecular, cellular biology and drug discovery; to advance our understanding of disease mechanisms and develop new therapies for neurological and psychiatric disorders through innovative research.
The Institute fosters collaboration between researchers across multiple disciplines, academic institutions and healthcare organisations to dramatically accelerate the translation of basic research into clinical practice. The building was opened by HRH The Princess Royal in June 2015.
The Maurice Wohl Clinical Neuroscience Institute is dedicated to advancing our understanding of the molecular, cellular and functional basis of neurological and psychiatric disorders and the discovery, implementation and evaluation of novel diagnostic tools and therapeutic interventions.
We possess an unparalleled patient resource, state-of-the-art facilities and world-renowned researchers and clinicians who will be focusing on three major goals:
- Determining the underlying genetic and environmental risk factors for disease
- Identifying tests for early diagnosis and biomarkers that measure disease progression
- Developing informative cellular and animal disease models of disease to accelerate drug discovery
At the heart of the Institute lies a network of patients, carers, clinicians and researchers, driving forward a shared mission to improve the lives of people who live with devastating and as yet incurable disorders.
We are very grateful to the following organisations for their generous support:
• The Maurice Wohl Charitable Foundation
• The Wolfson Foundation
• King’s College Hospital NHS Foundation Trust
• King’s Medical Research Trust
• Maudsley Charity
• The Garfield Weston Foundation